Unhealthily close ties between regulators and pharmaceutical companies. Another academic analysis showed that persons who work for the pharmaceutical industry and those who work for the US drug regulatory agency (FDA) have, over the years, developed a common culture. Regulators have become "pro-industry", having adopted the same views as pharmaceutical companies (a phenomenon referred to as "regulatory capture"), in particular by accepting that "there is a direct trade-off between drug safety and drug innovation" (7). In summary, "the political organizations of the global pharmaceutical industry have come to shape the conversation about how drugs ought to be regulated" (7).
展开▼
